ObjectiveTo explore the regulatory effect of Ganluqingwen prescription on inflammation and immunity by observing the clinical efficacy of Ganluqingwen prescription in the treatment of community-acquired pneumonia （CAP）， so as to provide a clinical basis for the treatment of CAP by traditional Chinese medicine （TCM）. MethodsA randomized controlled trial was conducted by selecting patients who were diagnosed with CAP and identified as wind-heat attacking lungs in Xinjiang Uygur Autonomous Region Hospital of TCM from January 2024 to May 2024 and assigning the patients to a control group （treated by western medicine treatment） or an experimental group （treated by Ganluqingwen prescription combined with western medicine）. The data of the enrolled patients before treatment， for three-day treatment， for seven-day treatment， and for 14-day treatment were collected， including basic information， medical history， pneumonia severity index （PSI） classification， and distribution and difference of laboratory and imaging information indexes. The peripheral blood specimens were collected from the patients. and the changes of inflammatory factors in peripheral blood were detected by using enzyme-linked immunosorbent assay （ELISA） reagent kits and flow-type multifactor microarrays to evaluate the clinical safety and efficacy of Ganluqingwen prescription in CAP. ResultsCompared with those in the groups before treatment， the total scores of TCM syndromes significantly decreased in both groups （P<0.05）. Compared with those in the control group after treatment， the total scores of TCM syndromes decreased more significantly in the experimental group （P<0.05）. Compared with the control group after treatment， the experimental group displayed a significantly reduced number of days of fever in patients （P<0.05）. Compared with those in the groups before treatment， the leukocyte， neutrophil counts， C-reactive protein （CRP）， procalcitonin （PCT）， interleukin （IL）-6， alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， creatinine （Cr）， creatine kinase （CK）， and creatine kinase isoenzymes （CK-MB） in both groups decreased （P<0.05） after treatment. Compared with that in the control group after treatment， the decrease of leukocyte， neutrophil counts， CRP， PCT， IL-6， ALT， AST， Cr， CK， and CK-MB was more pronounced in the experimental group （P<0.05）. Compared with those in the group before treatment， the partial pressure of carbon dioxide increased in the experimental group for 3 d of treatment （P<0.05）， and the standard alkali residual， actual alkali residual， standard bicarbonate concentration， and actual bicarbonate concentration increased in the experimental group for 7 d of treatment （P<0.05）. Compared with that in the group before treatment， D-dimer decreased in the control group for 7 d of treatment （P<0.05）. D-dimer and activated partial thromboplastin time （APTT） decreased in the experimental group for 3 d of treatment （P<0.05）， and D-dimer， fibrinogen （FIB）， and APTI significantly decreased in the group for 7 d of treatment （P<0.05）. Compared with the group for 3 d of treatment， the experimental group for 7 d of treatment showed decreased FIB （P<0.05）. Compared with those in the groups before treatment， the levels of inflammatory factors IL-4， IL-10， and IL-13 were elevated in the peripheral blood of the two groups after treatment， and the levels of B lymphocyte chemoattractant （BLC）， interferon gamma-induced protein 10 （IP-10）， tumor necrosis factor-alpha （TNF-α）， interferon-gamma （IFN-γ）， monocyte chemoattractant protein-1 （MCP-1）， CRP， IL-2， IL-6， IL-8， IL-17， IL-22， and IL-23p19 were significantly reduced （P<0.01）. Compared with the control group after treatment， the experimental group exhibited more significant improvement in indexes above （P<0.01）. ConclusionThe group treated by Ganluqingwen prescription combined with western medicine shows more significant effects on reducing total scores of TCM syndromes， lowering the ability of leukocyte and neutrophil counts， decreasing BLC， IP-10， TNF-α， IFN-γ， MCP-1， CRP， IL-2， IL-6， IL-8， IL-17， IL-22， and IL-23p19 in the peripheral blood of the patients， and elevating levels of IL-4， IL-10， and IL-13 than the group treated by western drugs alone.

ObjectiveTo explore the regulatory effect of Ganluqingwen prescription on inflammation and immunity by observing the clinical efficacy of Ganluqingwen prescription in the treatment of community-acquired pneumonia （CAP）， so as to provide a clinical basis for the treatment of CAP by traditional Chinese medicine （TCM）. MethodsA randomized controlled trial was conducted by selecting patients who were diagnosed with CAP and identified as wind-heat attacking lungs in Xinjiang Uygur Autonomous Region Hospital of TCM from January 2024 to May 2024 and assigning the patients to a control group （treated by western medicine treatment） or an experimental group （treated by Ganluqingwen prescription combined with western medicine）. The data of the enrolled patients before treatment， for three-day treatment， for seven-day treatment， and for 14-day treatment were collected， including basic information， medical history， pneumonia severity index （PSI） classification， and distribution and difference of laboratory and imaging information indexes. The peripheral blood specimens were collected from the patients. and the changes of inflammatory factors in peripheral blood were detected by using enzyme-linked immunosorbent assay （ELISA） reagent kits and flow-type multifactor microarrays to evaluate the clinical safety and efficacy of Ganluqingwen prescription in CAP. ResultsCompared with those in the groups before treatment， the total scores of TCM syndromes significantly decreased in both groups （P<0.05）. Compared with those in the control group after treatment， the total scores of TCM syndromes decreased more significantly in the experimental group （P<0.05）. Compared with the control group after treatment， the experimental group displayed a significantly reduced number of days of fever in patients （P<0.05）. Compared with those in the groups before treatment， the leukocyte， neutrophil counts， C-reactive protein （CRP）， procalcitonin （PCT）， interleukin （IL）-6， alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， creatinine （Cr）， creatine kinase （CK）， and creatine kinase isoenzymes （CK-MB） in both groups decreased （P<0.05） after treatment. Compared with that in the control group after treatment， the decrease of leukocyte， neutrophil counts， CRP， PCT， IL-6， ALT， AST， Cr， CK， and CK-MB was more pronounced in the experimental group （P<0.05）. Compared with those in the group before treatment， the partial pressure of carbon dioxide increased in the experimental group for 3 d of treatment （P<0.05）， and the standard alkali residual， actual alkali residual， standard bicarbonate concentration， and actual bicarbonate concentration increased in the experimental group for 7 d of treatment （P<0.05）. Compared with that in the group before treatment， D-dimer decreased in the control group for 7 d of treatment （P<0.05）. D-dimer and activated partial thromboplastin time （APTT） decreased in the experimental group for 3 d of treatment （P<0.05）， and D-dimer， fibrinogen （FIB）， and APTI significantly decreased in the group for 7 d of treatment （P<0.05）. Compared with the group for 3 d of treatment， the experimental group for 7 d of treatment showed decreased FIB （P<0.05）. Compared with those in the groups before treatment， the levels of inflammatory factors IL-4， IL-10， and IL-13 were elevated in the peripheral blood of the two groups after treatment， and the levels of B lymphocyte chemoattractant （BLC）， interferon gamma-induced protein 10 （IP-10）， tumor necrosis factor-alpha （TNF-α）， interferon-gamma （IFN-γ）， monocyte chemoattractant protein-1 （MCP-1）， CRP， IL-2， IL-6， IL-8， IL-17， IL-22， and IL-23p19 were significantly reduced （P<0.01）. Compared with the control group after treatment， the experimental group exhibited more significant improvement in indexes above （P<0.01）. ConclusionThe group treated by Ganluqingwen prescription combined with western medicine shows more significant effects on reducing total scores of TCM syndromes， lowering the ability of leukocyte and neutrophil counts， decreasing BLC， IP-10， TNF-α， IFN-γ， MCP-1， CRP， IL-2， IL-6， IL-8， IL-17， IL-22， and IL-23p19 in the peripheral blood of the patients， and elevating levels of IL-4， IL-10， and IL-13 than the group treated by western drugs alone.

Objective To construct the competitive endogenous RNA(ceRNA)network of chronic ob-structive pulmonary disease(COPD)related lung cancer by proteomics combined with bioinformatics technol-ogy,and to explore the biological mechanism and potential core therapeutic targets of the two diseases.Methods The clinical specimens of patients with COPD related lung cancer and patients with lung cancer were collected for proteomics analysis.The differentially expressed genes in COPD related lung cancer were screened and the protein interaction network(PPI)was constructed,and the above differentially expressed genes were enriched.The key genes of COPD related lung cancer were screened and verified in the gene ex-pression omnibus(GEO)database.Finally,the microRNA(miRNA)and long non-coding RNA(lncRNA)of differential proteins were predicted to construct the ceRNA network based on COPD related lung cancer.Re-sults The results of proteomics analysis showed that 211 differentially expressed proteins were down-regula-ted and 168 differentially expressed proteins were up-regulated.A total of 379 differentially expressed proteins were obtained and used to construct PPI.The COPD related microarray was searched in GEO database,and the results showed that a total of 929 differentially expressed genes were screened in GSE103174 dataset.A to-tal of 13 605 lung cancer related differentially expressed genes were obtained from GSE43346 dataset.Two COPD related lung cancer genes,OASL and ROGDI,were obtained by intersection of the above results with the previous proteomics analysis results.The receiver operating characteristic curve was used to analyze the di-agnostic value of OASL and ROGDI in lung cancer and COPD.The results showed that the area under the curve was 0.784,0.731,0.688 and 0.785,respectively,and the differences were statistically significant(P＜0.05).The lncRNA-miRNA-gene related ceRNA network of COPD-lung cancer was constructed.Conclusion OASL and ROGDI may be used as important biomarkers for the diagnosis and treatment of COPD-related lung canc-er.In addition,the constructed ceRNA network provides a new direction for further research on this disease.

Objective To investigate the action mechanism of Bufei Yiqi Tongluo formula in treating id-iopathic pulmonary fibrosis (IPF) based on the transforming growth factor-β1 (TGF-β1)/c-Jun N-terminal ki-nase (JNK) signaling pathway.Methods The key targets of network pharmacology conducted the enrichment analysis and the IPF rat model was constructed,which was divided into the blank control group,IPF model group and Bufei Yiqi Tongluo formula group.The pathological changes of lung tissue in various groups were observed,and the levels of white blood cells (WBC) in bronchoalveolar lavage fluid (BALF) were analyzed. The enzyme-linked immunosorbent assay (ELISA) was used to detect the protein expression levels of tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6),phosphorylated JNK (p-JNK)/JNK,TGF-β1,tissue inhibitor of metalloproteinases-1 (TIMP-1) and matrix metalloproteinase-9 (MMP-9) in serum,BALF and lung tissue. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of these proteins in serum,BALF and lung tissue.Results The network pharmacology enrichment analysis re-sults revealed that TGF-β1 and JNK signaling pathways were closely related with IPF.Compared with the IPF model group,the lung tissue orderliness in the Bufei Yiqi Tongluo formula group was increased,the consolida-tion range was decreased,the fibrotic tissue proliferation was significantly reduced,the WBC level and expres-sion levels of TNF-α and IL-6 in BALF were significantly decreased.Compared with the blank control group,the mRNA expression levels of TGF-β1,p-JNK/JNK,TIMP-1 and MMP-9 in serum,BALF and lung tissues in the IPF model group were increased with statistical difference (P<0.05).After the intervention on the model rats by the Bufei Yiqi Tongluo formula,except there was no difference in the expression level of MMP-9 pro-tein in serum,TGF-β1 in BALF,TIMP-1 in serum and MMP-9 mRNA in lung tissue,but the other indicators were decreased (P<0.05).Conclusion The therapeutic effect of Bufei Yiqi Tongluo formula in IPF may be related to its regulation on the TGF-β1/JNK signaling pathway.

Objective The material basis and pathway of CFTR regulation of sphingolipid metabolism in COPD were discussed,and the theory of lung channel regulation was further elucidated.Methods The mouse model of COPD was established by smoking method,and the CFTR model was established by smoking plus CFTR agonist.The pathological changes of lung tissues were observed and the mouse model was evaluated.Ceramide and sphingosine-1-phosphate expression of sphingolipid metabolites in plasma of the model were detected by LC-MS mass spectrometry.Western blot was used to detect the phosphorylation levels of Sphks,ASM and CFTR proteins in the lung tissue of the mouse model.Quantitative fluorescence PCR was used to detect the mrna transcription levels of Sphks,Smpd and CFTR mRNA in the lung tissue of the mouse model.Results The expression of S1p in COPD group and CFTR intervention group was lower than that in control group(P<0.05),and the expression of S1P in CFTR intervention group was higher than that in COPD group(P<0.05).The protein phosphorylation levels of CFTR and Sphk1 were low in COPD group and CFTR intervention group,the lowest expression in COPD group was different from that in control group and CFTR intervention group(P<0.05),and Sphk2 was different in COPD group and control group(P<0.05).ASM in COPD group and CFTR intervention group was higher than that in control group(P<0.05).CFTR mRNA in COPD group and CFTR intervention group was lower than that in control group,and there were differences between COPD group and control group(P<0.05).Sphk1 mRNA expression was the highest in control group,and there were differences between it and COPD group and CFTR intervention group(P<0.05).SMPD1 mRNA was highly expressed in COPD group and CFTR intervention group,and was different from control group(P<0.05).Conclusion To explore the material changes of pulmonary aqueduct dysfunction in COPD diseases,and to reveal the pathway of CFTR affecting water and fluid metabolism in COPD by participating in the regulation of sphingolipid metabolism.

In order to cope with the limitations of traditional algorithms,intelligent optimization algorithms have emerged,in which swarm intelligence algorithms have become the research focus.Herein gray wolf optimization algorithm,ant-lion optimization algorithm,sparrow search algorithm,dragonfly optimization algorithm,whale optimization algorithm,and grasshopper optimization algorithm are summarized in terms of mathematical models,improvement strategies and medical applications.Through in-depth literature comparison horizontally and vertically,it is found that the improved optimization algorithms are most widely used in the medicine,and the advantages of optimization algorithms are found to be beneficial to their subsequent medical applications.

Objective To explore the improving effect and mechanism of saikosaponin A on insomnia rats based on cAMP/PKA/CREB pathway.Methods Seventy-five SD rats were randomly divided into blank group,model group,low-dose saikosaponin A group(0.625 mg·kg-1),high-dose saikosaponin A group(2.500 mg·kg-1)and Estazolam group(0.1 mg·kg-1),with 15 rats in each group.Insomnia rat model was established by intraperitoneal injection of Phenylalanine(PCPA,0.1 mg·kg-1).The general condition and circadian rhythm of rats were observed;the sleep latency and sleep duration of rats were measured by pentobarbital sodium righting experiment.The sleep phase of rats was observed,and the duration of slow wave sleep phase 1(SWS1),slow wave sleep phase 2(SWS2),rapid eye movement sleep phase(REMS)and total sleep time(TST)were recorded.The mRNA expression levels of hypothalamic circadian genes Clock,Bmal1 and clock-controlled genes Rev-erbα and Rorα were determined by qRT-PCR.The expression level of NeuN in hippocampus was determined by immunofluorescence.The level of cAMP in brain tissue was determined by ELISA.The expression levels of Clock,Bmal1,Rev-erbα,Rorα and cAMP/PKA/CREB pathway-related proteins in brain tissue were determined by Western Blot.Results Compared with the blank group,the rats in the model group had disordered circadian rhythms,extreme excitement,irritability,and reduced sleep;the sleep latency was significantly prolonged(P＜0.05),and the sleep duration and SWS1,SWS2,REMS and TST were significantly shortened(P＜0.05).The arrangement of neurons was disordered,and the IOD value of NeuN positive neurons was significantly decreased(P＜0.05).The mRNA and protein expression levels of Clock,Bmal1,Rev-erbα and Rorα in brain tissue were significantly decreased(P＜0.05).The expression levels of cAMP,p-PKA/PKA and p-CREB/CREB in brain tissue were significantly decreased(P＜0.05).Compared with the model group,the aggressiveness of the rats in the administration group was significantly weakened,the circadian rhythm was rhythmic,the activity was reduced,and the sleep was increased.The sleep latency was significantly shortened(P＜0.05),and the sleep duration and SWS1,SWS2,REMS and TST were significantly prolonged(P＜0.05).The disorder of neuronal arrangement was restored,and the IOD value of NeuN positive neurons was significantly increased(P＜0.05).The mRNA and protein expression levels of Clock,Bmal1,Rev-erbα and Rorα in brain tissue were significantly increased(P＜0.05).The protein expression levels of cAMP,p-PKA/PKA and p-CREB/CREB in brain tissue were significantly increased(P＜0.05).Conclusion Saikosaponin A may improve the circadian rhythm of insomnia rats by activating cAMP/PKA/CREB pathway.

Objective To assess the methodology,reporting quality and intervention reporting quality of randomised controlled trials(RCT)of acupuncture for chronic obstructive pulmonary disease(COPD).Methods Randomized controlled trials of acupuncture for the treatment of chronic obstructive pulmonary disease from the establishment of the database to March 1,2023 through computer system search of CNKI,Wanfang,VIP,SinoMed,and PubMed databases.Two researchers independently conducted literature search,relevant data extraction,etc.,and assessed the quality of reports using the bias assessment tools ROB2,CONSORT Extended Statement and STRICTA List of Cochrane Systematic Review Manuals.Results After excluding non-compliant articles through the developed exclusion criteria,31 RCT remained.A methodological assessment of the included RCT according to the Cochrane website bias assessment tool ROB2 showed that 9 studies(29.03%)were at high risk of bias and no studies at low risk of bias.The CONSORT extended statement based on non-drug randomized controlled trials evaluated the quality of the literature,indicating that the reporting rate in terms of methods,results,trial protocol registration,etc.was low.The results of the evaluation according to the entries in the STRICTA list show that most of the literature does not describe the details of acupuncture and the background of the therapist in sufficient detail,but the reasonableness of acupuncture treatment is relatively complete.Conclusion At present,the quality of randomized controlled trials of acupuncture for COPD is generally low,and it is recommended that future researchers strictly follow the internationally recognized CONSORT statement and STRICTA list for trial protocol design and study result reporting.

Objective:To optimize the challenge scheme for establishing a stable mouse model of Artemisia annua pollen-induced allergic rhinitis. Methods:BALB/c mice were subcutaneously injected with 0.1 ml allergen extract containing 20 μg/ml Art a1 from Artemisia pollen on 1 d, 4 d and 7 d. One week after the sensitization, these mice were divided into three groups and intranasally challenged with Artemisia annua pollen allergen extract containing 500 μg/ml Art a1 for 7 (7 d group), 10 (10 d group) and 14 (14 d group) consecutive days, respectively. The first challenge was followed by another 7 days of challenge every four weeks. Blank control group was set up through sensitizing and challenging BALB/c mice with normal saline. Behavioral changes and nasal pathological changes were observed. The changes in humoral and cellular responses were also detected. After the first challenge cycle was decided, the challenge frequency was further optimized. Results:After the first challenge, the allergic symptoms of mice in 10 d group were significantly severe than those in 7 d and 14 d groups, and the levels of serum specific IgE antibody in 10 d and 14 d groups were significantly higher than that in 7 d group. After the second challenge, the mice in the three model groups still had obvious allergic symptoms as compared with the blank control group. There were obvious pathological changes in the nose, including epithelial cell proliferation, turbinate enlargement and inflammatory cell increase. Moreover, the level of serum specific IgE antibody increased significantly and the proliferation of antigen-specific IL-4 and IL-6 lymphocytes was significantly up-regulated, especially in 10 d and 14 d groups. The frequency of challenge had a great impact on the stability of the allergic model. The allergic symptoms of sensitized mice challenged every two weeks were significantly severe than those of mice challenged every four weeks and the level of serum antigen-specific antibody was also higher.Conclusions:This study optimized the first challenge cycle and challenge frequency for establishing a mouse model of Artemisia annua pollen-induced allergic rhinitis, which provided reference for the establishment of drug efficacy evaluation system for desensitization therapy.

The research observed the effect of Yiqigubiao Pill regulating inflammatory reaction mRNA expression in JAK/STAT pathway in COPD rats model and explored protective effect of Yiqigubiao pills in the treatment or auxiliary possible mechanism in COPD. 60 SFP Wistar rats were divided randomly into control group (CN), COPD model group (M) and Yiqigubiao Pill group (Yqgb). The rats in group M and group YQGB were establish by using the method of LPS and smoking as COPD, rats in group M and group CN were given normal saline intragastric administration, and rats in the YQGB group were given water solution intragastric administration at the corresponding dose, twice a day. After using drugs for 12 weeks, we used ELISA method to detect changes inIL-17a, IL-23, IFN-γ and RORγt expression in peripheral blood, RT-PCR method to detect changes in the expression of JAK1, JAK3, STAT1 and STAT3 mRNA in lung tissues. Compared with the group CN, the infiltration of inflammatory cells stained by HE in the experimental group was reduced, and the diameter of the bronchial lumen was broadened (P ＜ 0.01). Both of ELISA and RT-PCR results showed that, compared with group CN, the levels of IL-17a, IL-23 and RORγt, the levels of JAK1, JAK3, STAT1, and STAT3 mRNA were increased in group M. Compared with group M, the mRNA levels of above indicators in group Yqgb were decreased, and the difference was statistically significant (P ＜ 0.01). Correlation analysis revealed that JAK1, JAK3, STAT1 and STAT3 were associated with IL-17a, IL-23, and RORγt had statistical significance (P ＜ 0.05). Therefore, Yiqgubiao Pill can inhibit the inflammatory response in COPD rats model, and its mechanism may be associated with inhibition of JAK/STAT pathway.